Literature DB >> 4307884

Dapsone and peripheral motor neuropathy.

A C Saqueton, A L Lorincz, N A Vick, R D Hamer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1969        PMID： 4307884

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN： 0003-987X


× No keyword cloud information.
  10 in total

1.  How Clinically Relevant is Dapsone-related Peripheral Neuropathy?: An Overview of Available Data with Emphasis on Clinical Recognition.

Authors:  Morgan McCarty
Journal:  J Clin Aesthet Dermatol       Date:  2010-03

2.  Peripheral neuropathy: a side effect of sulphones.

Authors:  G Volden
Journal:  Br Med J       Date:  1977-05-07

3.  Antibiotic-induced neurotoxicity.

Authors:  Shamik Bhattacharyya; Ryan Darby; Aaron L Berkowitz
Journal:  Curr Infect Dis Rep       Date:  2014-12       Impact factor: 3.725

4.  Drug-induced peripheral neuropathies.

Authors:  Z Argov; F L Mastaglia
Journal:  Br Med J       Date:  1979-03-10

5.  Possible dapsone-induced peripheral neuropathy in dermatitis herpetiformis.

Authors:  A du Vivier; T Fowler
Journal:  Proc R Soc Med       Date:  1974-06

6.  Rapid improvement of dermatitis herpetiformis after elemental diet.

Authors:  J B van der Meer; N Zeedijk; H Poen; S C van der Putte
Journal:  Arch Dermatol Res       Date:  1981       Impact factor: 3.017

Review 7.  A comprehensive insight into the anti-inflammatory properties of dapsone.

Authors:  Mina Khalilzadeh; Maryam Shayan; Sina Jourian; Mohammad Rahimi; Mohammad Sheibani; Ahmad Reza Dehpour
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-09-20       Impact factor: 3.195

8.  The anti-inflammatory profile of dapsone in animal models of inflammation.

Authors:  A J Lewis; D K Gemmell; W H Stimson
Journal:  Agents Actions       Date:  1978-12

9.  Peripheral motor neuropathy caused by excessive intake of dapsone (Avlosulfon).

Authors:  I Rosén; R Sörnäs
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1982

Review 10.  Dapsone therapy for malaria during pregnancy: maternal and fetal outcomes.

Authors:  Bernard J Brabin; Teunis A Eggelte; Monica Parise; Francine Verhoeff
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.